ATE371020T1 - Virusenthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten - Google Patents

Virusenthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Info

Publication number
ATE371020T1
ATE371020T1 AT04030395T AT04030395T ATE371020T1 AT E371020 T1 ATE371020 T1 AT E371020T1 AT 04030395 T AT04030395 T AT 04030395T AT 04030395 T AT04030395 T AT 04030395T AT E371020 T1 ATE371020 T1 AT E371020T1
Authority
AT
Austria
Prior art keywords
virus
concentration
methods
containing compositions
preparations
Prior art date
Application number
AT04030395T
Other languages
English (en)
Inventor
Andreas Frei
Henry Kwan
Varda E Sandweiss
Gary J Vellekamp
Pui-Ho Yuen
Laureano L Bondoc
Frederick William Porter
John Chu-Tay Tang
Peter Ihnat
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE371020T1 publication Critical patent/ATE371020T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04030395T 1998-02-17 1999-02-12 Virusenthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten ATE371020T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
ATE371020T1 true ATE371020T1 (de) 2007-09-15

Family

ID=26698472

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06019642T ATE478945T1 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
AT04030395T ATE371020T1 (de) 1998-02-17 1999-02-12 Virusenthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
AT99906690T ATE341614T1 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06019642T ATE478945T1 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99906690T ATE341614T1 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Country Status (25)

Country Link
EP (4) EP1054955B1 (de)
JP (3) JP4358434B2 (de)
KR (5) KR100912362B1 (de)
CN (2) CN100374551C (de)
AR (3) AR020054A1 (de)
AT (3) ATE478945T1 (de)
AU (1) AU757976B2 (de)
BR (1) BR9908015A (de)
CA (2) CA2723040A1 (de)
CO (1) CO4820440A1 (de)
DE (3) DE69933433T2 (de)
DK (1) DK1054955T3 (de)
ES (2) ES2272053T3 (de)
HK (3) HK1073481A1 (de)
HU (1) HU226015B1 (de)
ID (1) ID28298A (de)
IL (2) IL137510A0 (de)
MY (1) MY141641A (de)
NO (1) NO20004104L (de)
PE (1) PE20000265A1 (de)
PL (1) PL197747B1 (de)
PT (1) PT1054955E (de)
SK (1) SK11842000A3 (de)
TW (1) TWI232107B (de)
WO (1) WO1999041416A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP1133316B1 (de) * 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Adenovirus-formulierungen zur gentherapie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU4346101A (en) * 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2002047726A2 (en) * 2000-12-12 2002-06-20 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
EP1453536A4 (de) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd Zusammensetzung zur konservierung von viren
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
US20030232018A1 (en) * 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
CA2586107A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
JP4621743B2 (ja) 2004-12-13 2011-01-26 カンジ，インコーポレイテッド 複製欠損アデノウイルスの産生のための細胞株
CN101155915B (zh) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
JP5097714B2 (ja) 2005-12-12 2012-12-12 カンジ，インコーポレイテッド Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター
AU2007240797B2 (en) * 2006-04-20 2013-05-23 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
ES2532015T3 (es) 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
AU2011336410B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Lyophilized viral formulations
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
MX361774B (es) 2013-04-25 2018-12-17 Janssen Vaccines & Prevention Bv Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
KR20170004966A (ko) * 2014-05-28 2017-01-11 에이전시 포 사이언스, 테크놀로지 앤드 리서치 바이러스 감소 방법
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3624844A1 (de) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
EP3681533A1 (de) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Verfahren zur sicheren induktion der immunität gegen rsv
CN114173827A (zh) * 2019-06-28 2022-03-11 武田药品工业株式会社 腺相关病毒纯化方法
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (de) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
ATE341614T1 (de) 2006-10-15
HK1028416A1 (en) 2001-02-16
JP2006166925A (ja) 2006-06-29
KR20010072547A (ko) 2001-07-31
CN100374551C (zh) 2008-03-12
WO1999041416A2 (en) 1999-08-19
KR100912362B1 (ko) 2009-08-19
KR20090038927A (ko) 2009-04-21
EP1054955A2 (de) 2000-11-29
EP1741777A1 (de) 2007-01-10
EP1526173B1 (de) 2012-11-21
AR020054A1 (es) 2002-04-10
EP1741777B1 (de) 2010-08-25
AU757976B2 (en) 2003-03-13
EP1526173A2 (de) 2005-04-27
DE69936948T2 (de) 2008-05-15
NO20004104D0 (no) 2000-08-16
BR9908015A (pt) 2001-04-24
PE20000265A1 (es) 2000-04-25
KR20080065615A (ko) 2008-07-14
EP1054955B1 (de) 2006-10-04
PL342847A1 (en) 2001-07-16
CA2320419A1 (en) 1999-08-19
JP4358434B2 (ja) 2009-11-04
ES2290613T3 (es) 2008-02-16
AR063315A2 (es) 2009-01-21
CO4820440A1 (es) 1999-07-28
HK1073481A1 (en) 2005-10-07
ID28298A (id) 2001-05-10
PL197747B1 (pl) 2008-04-30
DK1054955T3 (da) 2007-01-15
NO20004104L (no) 2000-10-17
MY141641A (en) 2010-05-31
EP1526173A3 (de) 2005-08-10
CN1297478A (zh) 2001-05-30
KR100862169B1 (ko) 2008-10-09
AR063314A2 (es) 2009-01-21
HU226015B1 (en) 2008-02-28
CA2320419C (en) 2011-02-08
DE69933433T2 (de) 2007-08-23
DE69933433D1 (de) 2006-11-16
CN101164623A (zh) 2008-04-23
HUP0100670A3 (en) 2003-10-28
CN101164623B (zh) 2012-11-14
IL137510A (en) 2012-10-31
TWI232107B (en) 2005-05-11
KR20090127947A (ko) 2009-12-14
IL137510A0 (en) 2001-07-24
KR100918187B1 (ko) 2009-09-22
PT1054955E (pt) 2007-01-31
HK1097413A1 (en) 2007-06-22
JP2010213727A (ja) 2010-09-30
EP1526174A2 (de) 2005-04-27
ATE478945T1 (de) 2010-09-15
CA2723040A1 (en) 1999-08-19
DE69942708D1 (de) 2010-10-07
KR100991683B1 (ko) 2010-11-04
WO1999041416A3 (en) 1999-11-18
SK11842000A3 (sk) 2001-05-10
HUP0100670A2 (hu) 2001-06-28
JP2002503484A (ja) 2002-02-05
EP1526174B1 (de) 2007-08-22
DE69936948D1 (de) 2007-10-04
AU2653899A (en) 1999-08-30
KR20080065614A (ko) 2008-07-14
EP1526174A3 (de) 2005-08-31
KR101018992B1 (ko) 2011-03-07
ES2272053T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
ATE341614T1 (de) Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE69837703D1 (de) Methoden zum nachweis und zur analyse von virus
ATE477270T1 (de) Verfahren und zusammensetzungen zur prävention und behandlung von anämie
DE19882430T1 (de) Korrektur von Emissions-Kontamination und Totzeitverlust
DE69921853D1 (de) Vorrichtung zur behandlung von abgas
ATE478138T1 (de) Verfahren zur inaktivierung von lipidumhüllten viren
DE60035497D1 (de) Verfharen zur konservierung von viren und mycoplasma
DE69822473D1 (de) Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen
DE69935326D1 (de) Zusammensetzungen enthaltend molybden zur steigerung des proteinanabolismus und der entgiftung
NO971495L (no) Svekkede virus og fremgangsmåte til deres fremstilling
DE69933121D1 (de) Methode, reagent und testsatz zur typisierung des genoms von papillomavirus
DE60017341D1 (de) Emulsion, und Verfahren zur Herstellung von Emulsionen und öligen Zusammensetzungen
DE60222233D1 (de) Prozessor und Verfahren zur Erhaltung der Verarbeitungsreihenfolge von Paketen basierend auf Paketstromkennungen
DE69631443D1 (de) Reagens zur untersuchung von viren-agglutination und kit zur untersuchung auf viren
DE60031826D1 (de) Trennung von Viren und Nachweis von Viren
ATE211928T1 (de) Verfahren zur inaktivierung von viren in proteinen
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
ATA4812000A (de) Mittel zur behandlung von hepatitis c
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus
DE19681235D2 (de) Verfahren zur Deaktivierung der HIV und anderer Viren
DE59813114D1 (de) BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen
DE60008697D1 (de) Verfahren zur Herstellung von 4-(P-methoxyphenyl)-2-amino-butane und Insektizide
JP2002519670A5 (ja) Ｃ型レトロウイルス感染の検出のための方法および組成物

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties